



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life-improving drugs. For more than 30 years, we've been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in over 80 countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug development process.

We help change people's lives for the better every single day. It's what we are passionate about.

## STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	\$112.80
Change (%)	▼ 1.1 (0.97%)
Volume	43,097
52 Week Low	\$79.49
Market Cap	\$7,400,668,902
Rolling EPS	1.25
PE Ratio	90.7779
Shares Outstanding	64,975,144
Data as of 02/21/19 12:36 p.m. ET	



## NEWS & EVENTS

Date	Title
------	-------

Date	Title
------	-------

02/04/19	PRA Health Sciences to Report Fourth Quarter 2018 Earnings
11/27/18	PRA Health Sciences Launches Pediatric Site Network
10/31/18	PRA Health Sciences, Inc. Reports Third Quarter 2018 Results and Updates 2018 Guidance

02/28/19 9:00 a.m. ET	Q4 2018 PRA Health Sciences Inc Earnings Conference Call
-----------------------------	----------------------------------------------------------

## SEC FILINGS

Filing Date	Form
02/14/19	SC 13G/A
02/13/19	SC 13G/A
02/12/19	SC 13G/A
02/06/19	SC 13G/A

## BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)